Pancreatic Cancer Research

ResearcherThomas Jefferson UniversityActive in the last 2 years

Harish Lavu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-8907-9242; OpenAlex author ID A5057922763. Sources: ClinicalTrials.gov.

Their work

Papers
33 (first author 0, last author 4)
Trials
4 (principal investigator on 3)
Grants
0
Labs led
1
Collaborators
74
Papers, trials and grants by year

2008: 1 trial · 2009: none · 2010: none · 2011: 2 papers · 2012: none · 2013: 1 paper · 2014: none · 2015: 1 paper, 1 trial · 2016: 1 paper, 1 trial · 2017: 1 paper · 2018: 4 papers · 2019: none · 2020: 4 papers · 2021: 2 papers, 1 trial · 2022: 4 papers · 2023: 3 papers · 2024: 3 papers · 2025: 4 papers · 2026: 3 papers

Papers 33

  1. Initial Site of Metastasis Influences Prognosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/cam4.71760↗
  2. Preoperative Glucose-to-Albumin Ratio as a Prognostic Marker for Survival in Pancreatic Cancer Patients Undergoing Pancreatectomy. Co-author DOI 10.1002/cam4.72256↗
  3. Survival Impact of Intraoperative Carbon Dioxide Dysregulation in Patients Undergoing Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/xcs.0000000000001760↗
  4. Clinical Implications of Mismatch Repair Deficiency in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/cam4.70960↗
  5. P53 Function Status Correlates With Overall Survival in Patients With Resected Pancreatic Cancer. Co-author DOI 10.1002/jso.70060↗
  6. Prognostic Properties of KRAS Gene Mutation Subtypes in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002458↗
  7. Gene Expression Profiling of Pancreatic Ductal Adenocarcinoma Cells in Hypercapnia Identifies SIAH3 as a Novel Prognostic Biomarker. Co-author DOI 10.3390/ijms26072848↗
  8. Early outcomes of MR-guided SBRT for patients with recurrent pancreatic adenocarcinoma. Co-author DOI 10.1186/s13014-024-02457-y↗
  9. The Clinical Implications of KRAS Mutations and Variant Allele Frequencies in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/jcm13072103↗
  10. Association of Mutant KRAS Alleles With Morphology and Clinical Outcomes in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.5858/arpa.2023-0005-oa↗
  11. Hypercapnic Tissue Gene Expression and Survival in Early-Stage Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/xcs.0000000000000552↗
  12. Repurposing the FDA-approved anthelmintic pyrvinium pamoate for pancreatic cancer treatment: study protocol for a phase I clinical trial in early-stage pancrea… Co-author DOI 10.1136/bmjopen-2023-073839↗
  13. Association of Pancreatic Adenocarcinoma Location With DNA Damage Response Status and Response to Platinum-Based Therapy. Co-author DOI 10.1200/po.22.00648↗
  14. KRAS mutation allele frequency threshold alters prognosis in right-sided resected pancreatic cancer. Last author DOI 10.1002/jso.26860↗
  15. A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable … Last author DOI 10.1097/sla.0000000000004669↗
  16. Angiotensin blockade therapy and survival in pancreatic cancer: a population study. Co-author DOI 10.1186/s12885-022-09200-4↗
  17. The WASH (Water or Saline at High Volumes) Trial: A Randomized Trial to Assess the Survival Impact of Extensive Peritoneal Lavage Using Distilled Water or Sali… Last author DOI 10.1245/s10434-022-11978-3↗
  18. Pancreatic Cancer-Associated Diabetes is Clinically Distinguishable From Conventional Diabetes. Co-author DOI 10.1016/j.jss.2020.12.015↗
  19. Margin-Positive Pancreatic Ductal Adenocarcinoma during Pancreaticoduodenectomy: Additional Resection Does Not Improve Survival. Co-author DOI 10.1245/s10434-020-09000-9↗
  20. Optimizing cancer cure dialog: an analysis of pancreatic cancer patients' views regarding survival and cure. Co-author DOI 10.1007/s00520-019-05214-0↗
  21. Effect of Hypercapnia, an Element of Obstructive Respiratory Disorder, on Pancreatic Cancer Chemoresistance and Progression. Co-author DOI 10.1016/j.jamcollsurg.2019.12.033↗
  22. Advanced Endoscopic Rescue of a Complication (Duodenojejunostomy Leak) After a Pylorus-Preserving Pancreaticoduodenectomy in a Post-Esophagectomy Patient with … Co-author DOI 10.1089/pancan.2019.0016↗
  23. ASO Author Reflections: Margin-Positive Pancreatic Ductal Adenocarcinoma During Pancreaticoduodenectomy: Additional Resection Does Not Improve Survival. Co-author DOI 10.1245/s10434-020-09031-2↗
  24. Common Hepatic Artery Abutment or Encasement Is an Adverse Prognostic Factor in Patients with Borderline and Unresectable Pancreatic Cancer. Co-author DOI 10.1007/s11605-017-3595-7↗
  25. A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2. Co-author DOI 10.1016/j.jamcollsurg.2017.12.052↗
  26. Symptom Clusters in Patients With Pancreatic Cancer Undergoing Surgical Resection: Part I. Co-author DOI 10.1188/18.onf.e36-e52↗
  27. Clinical Implications of Extensive Lymph Node Metastases for Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-018-6763-4↗
  28. Microscopic lymphovascular invasion is an independent predictor of survival in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jso.24723↗
  29. Pancreatic Cancer in Lynch Syndrome: A Case Report. Co-author DOI 10.1089/crpc.2016.0007↗
  30. Pancreatic ductal adenocarcinoma treatment--the past, present, and future. Co-author DOI 10.1053/j.seminoncol.2014.12.001↗
  31. Tumor recurrence is independent of pancreatic fistula in patients after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.jamcollsurg.2013.05.014↗
  32. The novel triad of dorsal agenesis of the pancreas with concurrent pancreatic ductal adenocarcinoma and nonalcoholic chronic calcific pancreatitis: a case seri… Last author DOI 10.1007/s11605-011-1542-6↗
  33. Serum monocyte chemoattractant protein-1 in pancreatic cancer. Co-author DOI 10.1155/2011/518394↗

Trials 4

  1. A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer Principal investigator NCT05055323↗
  2. WASH Trial: Intraoperative Lavage as a Treatment for Pancreatic Cancer Principal investigator NCT02757859↗
  3. Accelerated Recovery Pathway for Discharge After Surgery in Patients With Pancreatic Cancer Study chair NCT02517268↗
  4. Intraoperative Celiac Plexus Neurolysis for Patients With Operable Pancreatic and Periampullary Cancer Principal investigator NCT00806611↗

Closest collaborators

The 25 strongest of 74 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Charles J. Yeo · 30 shared papers, 2011–2026 · strength 4.74
  2. Avinoam Nevler · 16 shared papers, 2018–2026 · strength 3.41
  3. Aditi Jain · 5 shared papers, 2024–2025 · strength 1.27
  4. Wei Jiang · 5 shared papers, 2017–2025 · strength 0.86
  5. Richard Zheng · 4 shared papers, 2020–2026 · strength 0.78
  6. Jordan Michael Winter · 6 shared papers, 2017–2021 · strength 0.59
  7. Theresa Pluth Yeo · 5 shared papers, 2018–2023 · strength 0.57
  8. Andrea Feci · 2 shared papers, 2026 · strength 0.57
  9. Christopher William Schultz · 4 shared papers, 2020–2023 · strength 0.51
  10. David O. Nauheim · 4 shared papers, 2020–2022 · strength 0.50
  11. Faria Nusrat · 2 shared papers, 2024–2025 · strength 0.47
  12. Scott W. Keith · 3 shared papers, 2018–2022 · strength 0.38
  13. Eleanor Mancheski · 1 shared paper, 2026 · strength 0.36
  14. James A. Posey · 2 shared papers, 2023–2024 · strength 0.36
  15. Jonathan Robert Brody · 3 shared papers, 2018–2023 · strength 0.35
  16. Atrayee Basu Mallick · 2 shared papers, 2023–2024 · strength 0.34
  17. Ashley Wetzel · 1 shared paper, 2026 · strength 0.29
  18. Nader N Hanna · 1 shared paper, 2026 · strength 0.29
  19. Zachary Kaplan · 1 shared paper, 2025 · strength 0.28
  20. Adam C. Berger · 3 shared papers, 2013–2021 · strength 0.27
  21. Hui Chen · 1 shared paper, 2025 · strength 0.26
  22. Nitzan Zohar · 1 shared paper, 2025 · strength 0.26
  23. Geoffrey M. Kozak · 3 shared papers, 2017–2018 · strength 0.23
  24. Jeffrey D. Epstein · 3 shared papers, 2017–2018 · strength 0.23
  25. Hwyda A. Arafat · 2 shared papers, 2011–2022 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.